Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 11/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7333211 | 0.96 | HTR4 (0.46) | HTR4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1502018 | 0.91 | HTR4 (0.51) | HTR4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL14810092 | 0.85 | HTR4 (0.54) | HTR4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21003313 | 0.84 | KDM4E (0.44) | HTR4 | |
| SCHEMBL14810317 | 0.83 | HTR4 (0.48) | HTR4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5318231 | 0.82 | SMN1; SMN2 (0.45) | HTR4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8509459 | 0.80 | HTR4 (0.52) | HTR4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2944408 | 0.80 | HTR4 (0.50) | HTR4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL18019921 | 0.79 | HTR4 (0.34) | HTR4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5042500 | 0.79 | HTR4 (0.51) | HTR4HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406434-B | As 5-HT4Amide compounds of receptor agonists | 苏文生命科学有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3265459-B1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2019-05-15 | — | — | EP | disclosed |
| EP-3265459-B1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2019-05-15 | — | — | EP | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-02-22 | — | — | US | disclosed |
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-02-22 | — | — | US | disclosed |
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-02-22 | — | — | US | disclosed |
| EP-3265459-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2018-01-10 | — | — | EP | disclosed |
| US-5521314-A | CHEMICAL INTERMEDIATES FOR CENTRAL NERVOUS SYSTEM, ANTIEMETICS, ANTIPSYCHOTIC AGENTS OR NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-05-28 | — | — | US | disclosed |
| WO-1996010026-A1 | PHENYL-OXO-ALKYL-(4-PIPERIDINYL)BENZOATE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-04-04 | — | — | WO | disclosed |
| US-5502209-A | SIDE EFFECT REDUCTION, GASTROINTESTINAL | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1996-03-26 | — | — | US | disclosed |
| EP-0691341-A1 | Benzopyrancarboxamide derivatives, salt thereof, process for the preparation of same and use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1996-01-10 | — | — | EP | disclosed |
| EP-0389037-B1 | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-09-20 | — | — | EP | disclosed |
| US-5374637-A | Stimulate gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-12-20 | — | — | US | disclosed |
| EP-0625149-A1 | BENZOPYRAN, BENZOTHIOPYRAN AND BENZOFURAN DERIVATIVES AS 5-HT4 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993016072-A1 | BENZOPYRAN, BENZOTHIOPYRAN AND BENZOFURAN DERIVATIVES AS 5-HT4 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-08-19 | — | — | WO | disclosed |
| CN-1045781-A | N-(3-hydroxy-4-piperidinyl base) (Dihydrobenzofuranes, dihydro-2H-chromene or dihydrobenzo two English) carboxamides derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1990-10-03 | — | — | CN | disclosed |
| EP-0389037-A1 | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | HTR4 1/4885HTR3E 18/4885HTR3B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.